LakeShore Biopharma Announces US$15 Million Private Placement Financing

Core Viewpoint - LakeShore Biopharma Co., Ltd has announced a share and warrant purchase agreement with an institutional investor, aiming to raise US$15 million through the issuance of ordinary shares and warrants [1] Company Summary - The company is focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer [1] - The agreement involves the issuance of 16,987,542 ordinary shares at a price of US$0.883 per share and 16,987,542 warrants, each allowing the purchase of one ordinary share at an exercise price of US$1.079 over a 36-month period [1] Financial Details - The total amount raised through this private placement is US$15 million, which is exempt from registration under Regulation S of the Securities Act of 1933 [1] - The closing of the private placement is expected to occur soon after the parties agree to the Purchase Agreement, subject to customary conditions [1]